Oryzon Genomics SA is a clinical stage biopharmaceutical company, which engages in the discovery, research, and development of new chemical entities, as well as conducting clinical trials. The company is headquartered in Cornella De Llobregat, Barcelona and currently employs 47 full-time employees. The company went IPO on 2015-12-10. Its compounds in clinical development include iadademstat (ORY-lOOl), an LSD1 inhibitor that is in Phase II trials for the treatment of acute myeloid leukemia and small cell lung cancer; and vafidemstat (ORY-2001), an LSD1 inhibitor optimized for the Central Nervous System (CNS), in multiple Phase II clinical trials for the treatment of CNS and psychiatric illnesses. The firm also has ORY-3001, in preclinical development for the treatment of non-oncological diseases and has additional programs to develop inhibitors against other epigenetic targets.
Follow-Up Questions
Oryzon Genomics SA의 CEO는 누구입니까?
Don Carlos Manuel Buesa Arjol은 2002부터 회사에 합류한 Oryzon Genomics SA의 Executive Chairman of the Board입니다.
ORYZF 주식의 가격 성능은 어떻습니까?
ORYZF의 현재 가격은 $3.61이며, 전 거래일에 decreased 0% 하였습니다.
Oryzon Genomics SA의 주요 사업 주제나 업종은 무엇입니까?
Oryzon Genomics SA은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
Oryzon Genomics SA의 시가총액은 얼마입니까?
Oryzon Genomics SA의 현재 시가총액은 $279.8M입니다
Oryzon Genomics SA는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 9명의 분석가가 Oryzon Genomics SA에 대한 분석 평가를 실시했으며, 이는 3명의 강력한 매수, 6명의 매수, 1명의 보유, 0명의 매도, 그리고 3명의 강력한 매도를 포함합니다
